Get the Stockscreener App
12.16
4.56%
0.53
CorMedix Inc stock is traded at $12.16, with a volume of 2.15M.
It is up +4.56% in the last 24 hours and up +24.34% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$11.63
Open:
$11.81
24h Volume:
2.15M
Relative Volume:
0.80
Market Cap:
$958.07M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-13.22
EPS:
-0.92
Net Cash Flow:
$-38.74M
1W Performance:
-2.95%
1M Performance:
+24.34%
6M Performance:
+4.92%
1Y Performance:
+47.93%
1-Day Range:
$11.74
$12.29
1-Week Range:
$11.62
$13.02
52-Week Range:
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
12.16 | 916.32M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
Cormedix director Dunton sells $260k in shares - Investing.com
INSM Stock Up 78% in 6 Months: Here's What You Need to Know - Finviz
Surprises Report: What sentiment indicators say about CorMedix Inc stockJuly 2025 Highlights & Community Driven Trade Alerts - moha.gov.vn
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why - The Globe and Mail
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - The Globe and Mail
CorMedix price target raised to $18 from $17 at H.C. Wainwright - MSN
Can CorMedix's Melinta acquisition aid growth beyond DefenCath? - MSN
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? - Finviz
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? - Finviz
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? - sharewise.com
Responsive Playbooks and the CRMD Inflection - Stock Traders Daily
Meme Stocks: Is Adyen NV 1N8 stock attractive post correctionEarnings Recap Report & Safe Capital Allocation Plans - moha.gov.vn
CorMedix (CRMD): Evaluating Valuation After a Strong Multi‑Year Share Price Run - Sahm
CorMedix (CRMD): Assessing Valuation After a Strong Multi‑Year Share Price Run - Yahoo Finance
Why CorMedix could be the biopharma name to watch early in 2026 - MSN
CorMedix Builds a Real Revenue Story as DefenCath Adoption Accelerates - Investing.com
CorMedix Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Why CorMedix Could be the Biopharma Name to Watch Early in 2026 - sharewise.com
CorMedix Inc.'s (NASDAQ:CRMD) 28% Jump Shows Its Popularity With Investors - simplywall.st
CorMedix CEO Todisco sells $360,000 in CRMD stock - Investing.com India
CorMedix CEO Todisco sells $360,000 in CRMD stock By Investing.com - Investing.com Nigeria
CRMD SEC FilingsCormedix 10-K, 10-Q, 8-K Forms - Stock Titan
How CorMedix Inc. stock compares to market leadersWeekly Profit Summary & Fast Moving Stock Trade Plans - Улправда
Can CorMedix Inc. stock surprise with earnings upside2025 Growth vs Value & Weekly Breakout Watchlists - moha.gov.vn
Bear Alert: How CorMedix Inc. stock compares to market leadersMarket Growth Summary & Free Technical Confirmation Trade Alerts - Улправда
How rising interest rates impact CorMedix Inc. stockGDP Growth & Real-Time Sentiment Analysis - Улправда
How CorMedix Inc. stock reacts to global recession fears2025 Winners & Losers & Short-Term Swing Trade Alerts - Улправда
CEO Todisco Sells 30,000 ($360K) Of CorMedix Inc [CRMD] - TradingView — Track All Markets
Income Plays: Can CorMedix Inc. stock surprise with earnings upsideWeekly Trade Review & Accurate Intraday Trading Signals - Улправда
Will CorMedix Inc. (19KA) stock benefit from infrastructure billJuly 2025 Pullbacks & Low Risk Investment Opportunities - Улправда
Is It Too Late to Consider CorMedix After DefenCath Progress and Strong Price Gains? - Yahoo Finance
Will CorMedix Inc. (19KA) stock gain from lower interest rates2025 Historical Comparison & Fast Exit/Entry Strategy Plans - DonanımHaber
Sentiment Recap: Will CorMedix Inc. (19KA) stock gain from lower interest ratesJuly 2025 Retail & Safe Entry Point Identification - DonanımHaber
Is CorMedix Inc. stock a top pick in earnings season2025 Market Outlook & Smart Investment Allocation Insights - DonanımHaber
Will CorMedix Inc. (19KA) stock hit analyst forecastsWeekly Trade Review & Weekly High Potential Stock Alerts - DonanımHaber
Can CorMedix Inc. (19KA) stock surprise with quarterly resultsQuarterly Market Summary & AI Powered Buy/Sell Recommendations - ulpravda.ru
Breakout Move: How sustainable is CorMedix Inc. stock dividend payoutWeekly Stock Analysis & Risk Controlled Stock Alerts - Улправда
CorMedix announces interim results for DefenCath - TipRanks
Why Is CorMedix Stock Rising Today? - Asianet Newsable
CorMedix Says Interim DefenCath Study Data Show Fewer Infections - marketscreener.com
Cormedix reports positive data from real world study of Defencath - marketscreener.com
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath - The Manila Times
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy? - Yahoo Finance
(CRMD) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance - MSN
CRMD up more than 40% YTD: Time to buy, sell or hold the stock? - MSN
Cormedix Director Makes a Significant Stock Sale! - TipRanks
CorMedix Q3 2025 Earnings Preview - MSN
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):